Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1Phase 1/2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Carcinoma, Non-Small-Cell Lung 48Neoplasms 27Colorectal Neoplasms 26Neoplasm Metastasis 24Recurrence 22Ovarian Neoplasms 22Pancreatic Neoplasms 21Breast Neoplasms 20Squamous Cell Carcinoma of Head and Neck 18Prostatic Neoplasms 18Melanoma 17Glioblastoma 15Lymphoma, Large B-Cell, Diffuse 14Precursor Cell Lymphoblastic Leukemia-Lymphoma 13Lymphoma, Non-Hodgkin 13Endometrial Neoplasms 13Multiple Myeloma 12Lung Neoplasms 12Colonic Neoplasms 12Triple Negative Breast Neoplasms 11Carcinoma, Renal Cell 11Stomach Neoplasms 10Leukemia, Myeloid, Acute 10Glioma 10Gastrointestinal Neoplasms 10Rectal Neoplasms 9Lymphoma, Follicular 9Lymphoma 9Head and Neck Neoplasms 8Burkitt Lymphoma 8

Interventions

pembrolizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Tongue Neoplasms × 30 days × Clear all
NCT07552558 2026-06-03

Ficerafusp Alfa, Pembrolizumab, and Stereotactic Body Radiotherapy (SBRT) for Head and Neck Squamous Cell Carcinoma (HNSCC)

Washington University School of Medicine

Phase 1/2 Not yet recruiting
45 enrolled
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell, Head and Neck Neoplasms, Hypopharyngeal Neoplasms, Jaw Neoplasms, Laryngeal Neoplasms, Lip Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms, Tongue Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡